- Home
- FOUR vs EWTX Comparison
FOUR vs EWTX Comparison
Compare FOUR & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FOUR | EWTX |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.3B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FOUR | EWTX |
|---|---|---|
| Price | $58.59 | $30.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 7 |
| Target Price | ★ $95.87 | $34.71 |
| AVG Volume (30 Days) | ★ 2.0M | 780.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.64 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,330,600,000.00 | N/A |
| Revenue This Year | $28.63 | N/A |
| Revenue Next Year | $24.46 | N/A |
| P/E Ratio | $27.53 | ★ N/A |
| Revenue Growth | ★ 29.86 | N/A |
| 52 Week Low | $52.65 | $10.60 |
| 52 Week High | $107.16 | $31.29 |
Technical Indicators
Market Signals| Indicator | FOUR | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.18 | 58.56 |
| Support Level | $53.88 | $29.46 |
| Resistance Level | $59.89 | $31.20 |
| Average True Range (ATR) | 2.68 | 1.66 |
| MACD | 0.19 | -0.09 |
| Stochastic Oscillator | 66.67 | 74.83 |
Price Performance
Historical ComparisonAbout FOUR Shift4 Payments Inc.
Shift4 Payments Inc is provider of integrated payment processing and technology solutions. The company offers software providers a single integration to an end-to-end payments offering, a powerful gateway and a robust suite of technology solutions (including cloud enablement, business intelligence, analytics, and mobile) to enhance the value of their software suites and simplify payment acceptance. The company derives maximum revenue from United States.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.